The PBM ‘Black Box’ is Dead: How the CAA 2026 Ends Hidden Markups

TJ Bullock | March 13th, 2026

For decades, the world of Pharmacy Benefit Managers (PBMs) has been shrouded in what industry insiders call the "Black Box." It’s a place where drug prices are obscured, rebates are pocketed by middlemen, and employers are left wondering why their pharmacy spend is skyrocketing despite "discounts" on paper.

If you’re an employer with 25 to 300 employees, you’ve likely felt the frustration of being told your plan is "competitive," only to see a 15% renewal increase year after year. Here’s the reality: It’s not your plan, it’s how you’re paying for it.

The Consolidated Appropriations Act of 2026 (CAA 2026) has arrived to flip the lights on. This isn't just another compliance headache; it’s a massive shift in power from the PBMs back to the plan sponsors, that’s you. At Bullock & Associates, we believe in transparency, and the CAA 2026 is finally codifying what we’ve been preaching for years.

⸻

1️⃣ FULL DISCLOSURE OF ALL COMPENSATION: NO MORE HIDDEN FEES

• Translation: PBMs can no longer hide behind "proprietary" pricing. They must tell you exactly how they are making money from your plan.
• Translation: "Direct" and "Indirect" compensation must be reported, meaning those back-end payments from drug manufacturers are finally out in the open.
• Translation: This "delinking" of fees from drug prices prevents PBMs from profiting more when a drug costs more.

Historically, PBMs made money through "spread pricing", charging the employer one price for a drug and paying the pharmacy a lower price, then pocketing the difference. They also collected "Bona Fide Service Fees" (BFSFs) from manufacturers that were often calculated as a percentage of a drug’s list price. This created a perverse incentive: the more expensive the drug, the more the PBM made.

The CAA 2026 puts an end to this. PBMs are now restricted to flat service fees that are not based on drug prices. By requiring the disclosure of every penny of compensation, the law ensures that your broker and your PBM are working for you, not for the pharmaceutical companies.

2️⃣ MANDATORY 100% REBATE PASS-THROUGH

• Translation: Every single dollar in manufacturer rebates belongs to your health plan, not the PBM.
• Translation: This prevents PBMs from "steering" employees toward more expensive drugs just to collect a higher rebate.
• Translation: Your "net cost" of drugs will finally reflect the actual discounts negotiated in the market.

Rebates have long been the PBM’s favorite hiding spot. Manufacturers offer rebates to get their drugs on a "preferred" list (formulary). In the past, PBMs would keep a significant portion of these rebates as "administrative fees." Under the CAA 2026, 100% of these rebates, fees, and other remunerations must be passed through to the plan sponsor.

For a company with 100 employees, this transparency can lead to significant savings that can be reinvested into better benefits or lower premiums for staff. It removes the conflict of interest where a PBM might prefer a high-cost brand-name drug over a lower-cost generic simply because the brand-name drug carries a fat rebate.

3️⃣ ENHANCED AUDIT RIGHTS: THE POWER OF DATA

• Translation: You don't have to take their word for it anymore. You have the legal right to see the raw claims data.
• Translation: For employers with 100+ employees, semi-annual drug-level reporting is now mandatory.
• Translation: You can now see the "spread", the difference between what you paid and what the pharmacy received.

"Trust us" is no longer a valid business strategy for PBMs. The CAA 2026 empowers plan sponsors with enhanced audit rights. You are now entitled to see drug-level reporting that includes the compensation received by the PBM for each covered drug and the actual payments made to pharmacies.

At Bullock & Associates, we’ve always helped our clients understand their strategic benefit planning, but these new laws give us the teeth to hold vendors accountable. When you have the data, you can see if you’re being overcharged for common medications or if there are cheaper alternatives that are being blocked.

4️⃣ THE NEW FIDUCIARY STANDARD: SHOW US THE DATA

• Translation: Employers are legally responsible for ensuring pharmacy costs are "reasonable."
• Translation: You cannot fulfill your fiduciary duty if you don't know what you’re paying for.
• Translation: The shift from "Trust us" to "Show us the data" is now a federal mandate.

The Department of Labor (DOL) has made it clear: as a plan sponsor, you are a fiduciary. This means you have a legal obligation to act in the best interest of your plan participants. If you are paying $2,000 for a drug that is available for $200 at the pharmacy down the street, and you didn't check the data, you could be held liable.

The CAA 2026 provides the tools to meet this standard. By requiring PBMs to attest to their compliance and providing you with the necessary reporting, the law protects you from the "black box" while simultaneously demanding that you pay attention. It’s about taking control of your employer benefits and ensuring every dollar is spent wisely.

⸻

What Should Employers Do Now?

The landscape is changing fast. While some of these provisions have specific phase-in dates, the "best practice" window is already open. If you are renewing a contract or looking at new PBM options, you should be asking three critical questions:

1. Is our contract "Pass-Through"? If not, you are likely leaving money on the table.
2. Do we have full audit rights to the raw claims data? If the PBM says no, it's time to look for a new partner.
3. Are we receiving 100% of the rebates? Anything less is a hidden markup.

We understand that health insurance and pharmacy benefits can feel like an alphabet soup of acronyms and hidden traps. That’s why we’re here. Whether you’re looking to explore self-funding options or just want a second set of eyes on your current pharmacy spend, we’re ready to help.

As a UBA Partner Firm, Bullock & Associates has access to national data and expertise that allows us to benchmark your plan against the best in the country. We don't just look for higher deductibles; we look for better ways to fund the care your employees need.

The PBM "Black Box" is dead. Long live transparency.

Making complicated simple.

#UBA #NABIP #employeebenefits #PBMtransparency #CAA2026 #HealthInsurance #FiduciaryDuty #PharmacySavings

---